Compare Gilead Sciences, Inc. (GILD) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Gilead Sciences, Inc. trades at $149.89 (market cap $182.40B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Gilead Sciences, Inc. is far larger — about 21.5× Global X NASDAQ 100 Covered Call ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Global X NASDAQ 100 Covered Call ETF for 50 Days on average.
| GILD | QYLD | |
|---|---|---|
Market Cap | $182.40B | $8.49B |
Volume | 4,469,821 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $18.68 |
52-Week Low | $116.74 | $16.70 |
Typical Hold Time | 111 Days | 50 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
QYLD trades at $18.675, down slightly by 0.03% on the day. The ETF shows a bullish technical signal from moving averages but bearish oscillators, with RSI levels indicating potential overbought conditions. Recent dividend payments of $0.18 per share were distributed monthly, supporting its income-focused strategy. News coverage highlights its high yield but also raises concerns about long-term capital erosion and capped upside.
The outlook for QYLD is mixed; it offers attractive monthly income but faces headwinds from declining option premiums and limited growth potential. Risks include principal erosion and tax implications, making it suitable for income-seeking investors who prioritize cash flow over capital appreciation. Analyst sentiment varies, with some upgrades citing yield attractiveness amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
